Imperial College London
Alternate

Professor Toby Maher

Faculty of Medicine, National Heart & Lung Institute

Professor of Interstitial Lung Disease
 
 
 
//

Contact

 

+44 (0)20 7594 2151t.maher

 
 
//

Assistant

 

Ms Georgina Moss +44 (0)20 7594 2151

 
//

Location

 

364Sir Alexander Fleming BuildingSouth Kensington Campus

//

Summary

 

Publications

Citation

BibTex format

@article{Kreuter:2020:10.1186/s12931-020-1298-1,
author = {Kreuter, M and Wuyts, WA and Wijsenbeek, M and Bajwah, S and Maher, TM and Stowasser, S and Male, N and Stansen, W and Schoof, N and Orsatti, L and Swigris, J},
doi = {10.1186/s12931-020-1298-1},
journal = {Respiratory Research},
title = {Health-related quality of life and symptoms in patients with IPF treated with nintedanib: analyses of patient-reported outcomes from the INPULSIS® trials},
url = {http://dx.doi.org/10.1186/s12931-020-1298-1},
volume = {21},
year = {2020}
}
Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - BACKGROUND: In the Phase III INPULSIS® trials, treatment of patients with idiopathic pulmonary fibrosis (IPF) with nintedanib significantly reduced the annual rate of decline in forced vital capacity (FVC) versus placebo, consistent with slowing disease progression. However, nintedanib was not associated with a benefit in health-related quality of life (HRQoL) assessed using the St George's respiratory questionnaire (SGRQ). We aimed to further examine the impact of IPF progression on HRQoL and symptoms, and to explore the effect of nintedanib on HRQoL in patients from the INPULSIS® trials stratified by clinical factors associated with disease progression. METHODS: Patient-reported outcome (PRO) data from the INPULSIS® trials were included in three post hoc analyses. Two analyses used the pooled data set to examine PRO changes from baseline to week 52 according to 1) decline in FVC and 2) occurrence of acute exacerbations. In the third analysis, patients were stratified based on clinical indicators of disease progression (gender, age and physiology [GAP] stage; FVC % predicted; diffusing capacity of the lung for carbon monoxide [DLCO] % predicted; composite physiologic index [CPI]; and SGRQ total score) at baseline; median change from baseline was measured at 52 weeks and treatment groups were compared using the Wilcoxon two-sample test. RESULTS: Data from 1061 patients (638 nintedanib, 423 placebo) were analyzed. Greater categorical decline from baseline in FVC % predicted over 52 weeks was associated with significant worsening of HRQoL and symptoms across all PRO measures. Acute exacerbations were associated with deterioration in HRQoL and worsened symptoms. In general, patients with advanced disease at baseline (defined as GAP II/III, FVC ≤ 80%, DLCO ≤ 40%, CPI >  45, or SGRQ > 40) experienced greater deterioration in PROs than patients with less-advanced disease. A
AU  - Kreuter,M
AU  - Wuyts,WA
AU  - Wijsenbeek,M
AU  - Bajwah,S
AU  - Maher,TM
AU  - Stowasser,S
AU  - Male,N
AU  - Stansen,W
AU  - Schoof,N
AU  - Orsatti,L
AU  - Swigris,J
DO  - 10.1186/s12931-020-1298-1
PY  - 2020///
SN  - 1465-9921
TI  - Health-related quality of life and symptoms in patients with IPF treated with nintedanib: analyses of patient-reported outcomes from the INPULSIS® trials
T2  - Respiratory Research
UR  - http://dx.doi.org/10.1186/s12931-020-1298-1
UR  - https://www.ncbi.nlm.nih.gov/pubmed/32000772
UR  - http://hdl.handle.net/10044/1/77017
VL  - 21
ER  -
Download